- Home
- VMC vs ONC Comparison
VMC vs ONC Comparison
Compare VMC & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VMC | ONC |
|---|---|---|
| Founded | 1909 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.2B | 31.4B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | VMC | ONC |
|---|---|---|
| Price | $288.24 | $327.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $323.17 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 980.7K | 362.7K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 18.39 | N/A |
| EPS | ★ 1.26 | N/A |
| Revenue | ★ $7,781,900,000.00 | N/A |
| Revenue This Year | $1.85 | $723.76 |
| Revenue Next Year | $6.22 | $15.04 |
| P/E Ratio | ★ $225.79 | $614.06 |
| Revenue Growth | ★ 6.38 | N/A |
| 52 Week Low | $252.35 | $253.95 |
| 52 Week High | $331.09 | $385.22 |
Technical Indicators
Market Signals| Indicator | VMC | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 70.57 |
| Support Level | $281.78 | $325.47 |
| Resistance Level | $288.98 | $328.39 |
| Average True Range (ATR) | 7.41 | 8.14 |
| MACD | -1.04 | 1.64 |
| Stochastic Oscillator | 53.98 | 89.85 |
Price Performance
Historical ComparisonAbout VMC Vulcan Materials Company (Holding Company)
Vulcan Materials is the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). Its largest markets include Texas, California, Virginia, Tennessee, Georgia, Florida, North Carolina, and Alabama. In 2024, Vulcan sold 219.9 million tons of aggregates, 13.6 million tons of asphalt mix, and 3.6 million cubic yards of ready-mix. As of Dec. 31, 2024, the company had 16.5 billion tons of aggregate reserves.
About ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.